Core Viewpoint - Adicon Holdings (09860) has seen a significant stock price increase, rising over 37% in early trading and currently up 21.85% to HKD 6.58, with a trading volume of HKD 68.54 million [1] Group 1: Acquisition Details - In November of last year, Adicon announced the acquisition of 100% equity in Crown Bioscience for USD 204 million, expected to be completed by mid-2026 [1] - Crown Bioscience specializes in translational oncology and immuno-oncology, possessing the largest commercial PDX model library globally and serving over 1,100 clients, including the top 20 pharmaceutical companies [1] Group 2: Strategic Implications - According to the latest report from Jefferies, Adicon's strategic positioning in AI medical testing and the acquisition of Crown Bioscience will significantly enhance its comprehensive strength in the drug development and diagnostic value chain [1] - The acquisition is expected to substantially improve Adicon's capabilities in preclinical and translational research, leveraging Crown's extensive data assets and bioinformatics expertise to further solidify its industry position [1] - Post-acquisition, it is anticipated that approximately 23% of Adicon's revenue will come from overseas markets [1]
港股异动 | 艾迪康控股(09860)早盘涨超37% 机构称收购中美冠科将显著强化公司综合实力